Loading...
XASX
ACR
Market cap4mUSD
Aug 28, Last price  
0.01AUD
Name

Acrux Ltd

Chart & performance

D1W1MN
XASX:ACR chart
P/E
P/S
1.27
EPS
Div yield, %
Shrs. gr., 5y
13.99%
Rev. gr., 5y
28.28%
Revenues
Net income
CFO
Dividend
Aug 18, 20150.06 AUD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Acrux Limited, alongside its affiliated entities, specializes in the global development and commercialization of generic and topical pharmaceutical products. The company's reach extends across international markets, including Australia, Europe, and the United States. A significant part of its offerings includes diverse testosterone therapies, available in various forms such as oral and buccal tablets, subcutaneous pellets, transdermal patches, injections, and topical gels, all aimed at treating adult men with low or absent testosterone levels. Additionally, Acrux provides estradiol sprays, sold under the brand names Evamist and Lenzetto, specifically formulated for women experiencing hot flashes associated with menopause. The company, established in 1998, is headquartered in West Melbourne, Australia.
IPO date
Sep 29, 2004
Employees
43
Domiciled in
AU
Incorporated in
AU

Valuation

No data to show